Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
29.96
-1.48 (-4.71%)
At close: Nov 20, 2026, 4:00 PM EST
30.20
+0.24 (0.80%)
After-hours: Nov 20, 2026, 5:33 PM EST
Viridian Therapeutics Employees
Viridian Therapeutics had 252 employees as of December 31, 2025. The number of employees increased by 109 or 76.22% compared to the previous year. That makes Viridian Therapeutics the 25,191st largest employer in the world and 3,207th in the United States.
Employees
252
Change (1Y)
109
Growth (1Y)
76.22%
Revenue / Employee
$104,401
Profits / Employee
-$1,577,778
Market Cap
3.40B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 252 | 109 | 76.22% | 252 | 0 |
| Dec 31, 2024 | 143 | 49 | 52.13% | 143 | 0 |
| Dec 31, 2023 | 94 | 8 | 9.30% | 94 | 0 |
| Dec 31, 2022 | 86 | 36 | 72.00% | 86 | 0 |
| Dec 31, 2021 | 50 | 23 | 85.19% | 50 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 3,300 |
| Iovance Biotherapeutics | 975 |
| AbCellera Biologics | 562 |
| Xenon Pharmaceuticals | 370 |
| Tarsus Pharmaceuticals | 370 |
| Arcutis Biotherapeutics | 354 |
| Relay Therapeutics | 218 |
| Disc Medicine | 173 |
VRDN News
- 1 day ago - Viridian Therapeutics initiated with a Buy at BofA - TheFly
- 1 day ago - Viridian Therapeutics initiated with a Buy at BofA - TheFly
- 4 days ago - Viridian Therapeutics Transcript: Jefferies Global Healthcare Conference - Transcripts
- 10 days ago - Viridian Therapeutics price target raised to $39 from $34 at Wells Fargo - TheFly
- 11 days ago - Viridian Therapeutics Transcript: Study update - Transcripts
- 11 days ago - Viridian Therapeutics Press release: Study update - Filings
- 11 days ago - Viridian Therapeutics Slides: Study update - Filings
- 11 days ago - Viridian Therapeutics announces phase 1 results for VRDN-008 - TheFly